| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5503871 | Parkinsonism & Related Disorders | 2016 | 7 Pages |
Abstract
In this phase 2 study, preladenant used as adjunctive therapy in PD patients on stable doses of levodopa did not reduce mean OFF time; treatment was well tolerated at doses between 2 and 10Â mg BID.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Nobutaka Hattori, Masashi Kikuchi, Noriaki Adachi, David Hewitt, Susan Huyck, Tadayuki Saito,